Recently, the U.S. Food and Drug Administration (FDA) has announced it will begin phasing out certain animal testing requirements for drug development—starting with monoclonal antibody therapies and similar treatments. The initiative is aimed at improving drug safety and accelerating the approval process by embracing more effective, human-relevant alternatives.
The FDA’s new approach integrates advanced technologies such as AI-based computational toxicity models and lab-based methods like cell lines and organoid testing—collectively known as New Approach Methodologies (NAMs). These alternatives are designed to reduce, refine, or potentially replace traditional animal testing. According to the FDA, this transition could significantly lower R&D costs, ultimately making treatments more affordable for patients.
The updated strategy will take immediate effect for investigational new drug (IND) applications. Sponsors are now encouraged to include NAMs data as part of their submissions. In addition, the FDA plans to use real-world safety data from other countries with similar regulatory standards to help evaluate a drug’s efficacy and safety when it has already been studied in human populations abroad.
However, not all drugs are affected by this change—testing requirements for certain products, such as sunscreens, will remain in place for now.
The Personal Care Products Council responds to this act: “We agree with the FDA that continued reliance on outdated animal testing models is unnecessary and inefficient, and we urge FDA to extend this ban to cosmetics and over-the-counter (OTC) drugs, such as sunscreen products, as well.”
